Skip to main content
. 2024 Nov 3;15:20406207241292508. doi: 10.1177/20406207241292508

Figure 1.

Figure 1.

Mean (SD) and median serum concentration-time profiles for the crizanlizumab 5.0 and 7.5 mg/kg dose groups at (a) starting dose (up to day 15 post-dose) and (b) steady state (up to day 29 post-dose).

The pharmacokinetic analysis set included all patients who received at least one planned treatment of 5.0 or 7.5 mg/kg and provided at least one corresponding evaluable PK concentration. SD, standard deviation.